Projects
Exploration of the therapeutic potential of protein phosphatases involved in chromatin signaling. KU Leuven
Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseases KU Leuven
Inflammatory bowel diseases (IBD) are chronic, relapsing, inflammatory conditions of the gastrointestinal (GI) tract. Ulcerative colitis (UC) and Crohn’s disease (CD) are the primary subtypes of IBD. Although the etiology remains incompletely understood, it is generally accepted that IBD is the result of an inappropriate host response to environmental factors in genetically susceptible individuals. In Western Europe, prevalence of UC is ...
Implementation preclinical evaluation methods for therapeutic radiopharmaceuticals with CXCR4 and SSTR2 as target KU Leuven
Unlocking Therapeutic Potential: Harnessing Extracellular Vesicles and miRNAs to Combat Muscle Wasting Disorders KU Leuven
Approximately 40% of the human body’s mass is comprised of skeletal muscle, making it the largest organ in the human body. These muscles play a crucial role in providing stability, supporting movement, and maintaining the integrity of internal organs. Importantly, skeletal muscles possess the inherent ability to grow and regenerate, whether in response to injury or as a result of physiological conditions such as exercise. This study explores ...
Towards novel therapeutic strategies in ischemic stroke by targeting von Willebrand factor and promoting fibrinolysis KU Leuven
Ischemic stroke is worldwide the second most common cause of death and the leading cause of permanent disability. In order to improve therapeutic and prophylactic therapy, it is imperative to understand what causes ischemic stroke and how ischemic stroke brain damage progresses. Up until recently, little was known about the thrombi that cause ischemic stroke. Moreover, experimental and clinical data have demonstrated progression of ischemic ...
An on-chip single B cell mining platform for rapid development of fully human therapeutic antibodies and for immunoprofiling human antibody responses KU Leuven
Non-viral gene transfer for in vivo production of therapeutic antibodies: Antibody characterization, vector biosafety and anti-HER2 antibody combination therapy KU Leuven
Rational design and synthesis of non-hallucinogenic psilocin analogues as selective 5-HT2A receptor agonists with therapeutic potential Ghent University
Depression has become a major socio-economic burden. This mental disorder affects 5% of the adults and it is a major contributor to long-term disability and disease. It has become clear that first-line antidepressants such as SSRIs, SNRIs, and NRIs are not effective enough; 30% of adults relapse after treatment and patients often need to deal with serious side effects. There is a clear need for better therapeutics. Several studies on ...